In 2022, Empyrean made a significant leap forward with the acquisition of Morpheus™, a state-of-the-art, robotically assisted platform for Brachytherapy and Intraoperative Radiotherapy (IORT). The introduction of Morpheus™ to the market was met with resounding enthusiasm, establishing vital partnerships with numerous cancer centers. The allure of Morpheus™ lies in its versatility, advanced mobility, precise imaging capabilities, innovative beam sculpting, and the support of a robotic arm, making it a versatile tool in the fight against cancer. With the acquisition of Morpheus™, the Empyrean team saw an opportunity to enhance its features to better suit the market needs. Morpheus™ 2.0 is being prepared to be submitted to the FDA and other global regulatory bodies for applications across a wide array of lesions, tumors, and conditions where radiosurgery is indicated.

“Morpheus 2.0 is not currently for sale. Upon completion of the design, Morpheus™ 2.0 will soon be submitted to the FDA. For any inquiries relating to this product, please contact Empyrean’s research and development department.”

Delivers a Modern Workflow
• Integrated, cloud-based TPS *
• Minimal set-up; no internal shielding
• Rapid dose delivery; < 20 mins total workflow
• Automated robotic source insertion/extraction
• Minimized time under anesthesia
• ZeroGTM floating treatment head manipulation
• Robotically assisted system physics
• Compact. Fits through a standard door
• Mobile with a self-propulsion system

Increases Therapeutic Value
• Integrated tomosynthesis imaging *
• Patented beam forming technology
• Precise target volume definition, avoiding organs at risk
• Modulate energy 50-100kV for depth *
• FLASH capable (>70 Gy/sec) *
• RespiraTrackTM respiratory motion tracking
• Immediate post-operative treatment prior to
additional adjuvant therapies

Unlocks New Treatment Possibilities
• Design unlocks new possibilities for breast, colorectal, liver, spine, and vaginal RT treatment
• Our community of world class luminaries will advance treatment protocols

RAPID
Integrated, cloud-based treatment planning*, no internal shielding, and beam delivery in seconds truly modernizes IORT.

DIRECTIONAL
Highly precise, patented beam-sculpting technology with rapid delivery capability. Ability to spare healthy tissue and organs at risk, while providing a therapeutic dose.

CONFORMAL
On-board tomosynthesis * ensures uniform tissue conformance with treatment depths ranging from 50kV-100kV *.